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ABSTRACT 
 
 
 Human immunodeficiency virus (HIV) infection, despite great advances in 
antiretroviral therapy (ART), remains a lifelong affliction. Though current treatment 
regimens can effectively suppress viral load to undetectable levels and preserve healthy 
immune function, they cannot fully alleviate all symptoms caused by the presence of the 
virus, such as HIV-associated neurocognitive disorders (HAND). Exosomes are small 
vesicles that transport cellular proteins, RNA, and small molecules between cells as a 
mechanism of intercellular communication. Recent research has shown that HIV proteins 
and RNA can be packaged into exosomes and transported between cells, to pathogenic 
effect. This review summarizes the current knowledge on the diverse mechanisms 
involved in the sorting of viral elements into exosomes and the damage those exosomal 
agents can inflict. In addition, potential therapeutic options to counteract exosome-
mediated HIV pathogenesis are reviewed and considered. 
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CHAPTER 1.    INTRODUCTION 
 
 
HIV Life Cycle and Pathogenesis 
 
Since the discovery of human immunodeficiency virus (HIV) as the causative 
agent in the AIDS epidemic of the 1980s and 90s, advancements in antiretroviral therapy 
(ART) have vastly improved life expectancy and quality of life for HIV-infected 
individuals. However, being a lifelong infection, HIV continues to present a significant 
threat to public health. The Centers for Disease Control determined that there were 
approximately 974,000 people in the United States living with diagnosed HIV infection 
in 2015, with approximately 40,000 new cases being diagnosed annually since 20111. 
This large infected population faces a number of additional health concerns such as ART-
induced toxicity, toxic drug-drug interactions, viral resurgence due to poor ART 
adherence, neurocognitive dysfunctions, and the rising occurrence of drug resistance in 
some HIV strains, which all present a growing healthcare challenge2. 
 
HIV primarily infects CD4+ T-lymphocytes, as well as other immune cells, 
mediating entry through binding with the cell surface receptors CCR5 or CXCR4. The 
virus then fuses with the cell’s plasma membrane, uncoating and releasing its genome 
and the key structural enzymes reverse transcriptase and integrase, which convert the 
viral RNA genome into DNA and incorporate it into the host cell’s DNA, respectively. 
The viral genome can remain in the host cell for long periods in latency in which it does 
not replicate, before transcription is eventually reactivated in earnest by the viral protein 
Tat. A number of different viral mRNAs are produced through alternative splicing, and 
are translated into fifteen separate proteins which assemble into an immature virion. The 
new virion is released from the cell and matures extracellularly3. This process is lethal for 
the infected T-cell, and systemic immunosuppression occurs in the acute phase of HIV 
infection as the circulating lymphocyte population plummets4, though some T-cells 
survive long enough for HIV to revert into an inactive resting state, transitioning the virus 
back into the latent stage of infection5. The current standard for ART is treatment with a 
cocktail of drugs that each inhibit a separate stage of the viral life cycle: entry and fusion 
inhibitors block the virus in the first stage of infection, nucleoside and non-nucleoside 
reverse transcriptase inhibitors prevent the RNA-to-DNA conversion of the viral genome, 
integrase inhibitors prevent incorporation of the viral DNA into the host genome, and 
protease inhibitors prevent the maturation of virions6,7. Combination therapy with 
multiple types of antiretroviral drugs helps to prevent drug resistance mutations by 
providing several simultaneous barriers to reproduction7. 
 
Some strains and quasi-species of HIV are also macrophage-tropic, likely due to 
phenotypic changes in CD4 and co-receptor binding8. Macrophages are long-lived and 
able to survive persistent HIV infection, allowing them to serve as viral reservoirs for 
long-term latent infection5,9. Macrophages are also capable of trafficking to the central 
nervous system, transporting the virus across the otherwise impermeable blood-brain 
barrier (BBB) and allowing it to spread to microglia, the resident phagocytes of the brain. 
This phenomenon of viral transit to the brain was originally described by Haase shortly 
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after the discovery of HIV with the moniker “The Trojan Horse Hypothesis”10. Once in 
the brain, the presence of the virus causes neuroinflammation, astrocytosis, and 
neurodegeneration, which can lead to a spectrum of neurological conditions collectively 
referred to as HIV-associated neurocognitive disorders (HAND)11,12. HIV patients on 
regular ART have a reduced risk of severe neurocognitive impairment compared to 
patients who do not have access to ART, but still greater incidence of neurological 
symptoms compared to the uninfected population13,14. Furthermore, ART has not been 
able to reduce the frequency of neurocognitive disorders in HIV patients, though it has 
significantly reduced their overall severity15. ART penetration into the central nervous 
system is generally correlated with better cognitive performance16, however there is some 
controversy on that point, as some studies have failed to reproduce that relationship17. 
There is also disagreement on whether neurocognitive impairment in HIV patients 
receiving ART is necessarily a product of viral replication in the central nervous system, 
or a product of sustained neuroinflammation or another neurotoxic byproduct of HIV 
infection18. 
 
Considering this, the inability of current ART regimens to eliminate the 
symptoms of HIV-induced neurodegeneration, despite healthy resting CD4 counts and 
undetectable viral loads in HIV patients, could be due not to insufficient ART penetration 
and uncontrolled viral replication, but rather to another mechanism of viral pathogenesis 
that is not yet completely understood. One such mechanism, the subject of only recent 
investigation, is the potential role that exosomes may play in contributing to replication, 
secretion, and/or toxicity during HIV infection. 
 
 
Exosome Biogenesis and Function 
 
Exosomes are small membrane-bound vesicles, approximately 100 nm in 
diameter, that are secreted from and taken up by almost every type of cell19. They are 
born out of the endocytic pathway: clathrin-mediated invagination of the plasma 
membrane causes formation of an early endosome, which in turn buds inwards and forms 
multiple intraluminal vesicles20,21. This multivesicular body (MVB) then, instead of 
fusing with a lysosome and having its contents digested, returns to fuse with the plasma 
membrane and release those vesicles into the extracellular space as exosomes22. 
Originally believed to be a mechanism of waste disposal for the elimination of proteins 
from the plasma membrane23,24, it has since been discovered that exosomes also serve as 
mediators of intercellular communication by transporting proteins, RNA, and small 
molecules25. The packaging of exosomes with these biological cargo is likely not only 
undirected capture of membrane-bound and cytosolic proteins and RNA, but also a 
specific and directed process of cargo sorting. The endosomal sorting complex required 
for transport (ESCRT), an ancient and evolutionarily conserved complex of proteins that 
mediates scission of lipid membranes and is involved in MVB formation and exosome 
release26, has been shown to interact with both protein and RNA trafficking machinery to 
facilitate vesicle packaging27. There is also evidence of ESCRT-independent directed 
packaging of some exosomal cargo, mediated by membrane tetraspanins such as CD63 
and CD81, two reliable exosomal marker proteins28. 
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Once released, exosomes diffuse through body fluids such as blood, saliva, 
lymph, and spinal fluid until they come into contact with recipient cells29. The recipient 
cells can then either take in the exosomes and their contents by multiple mechanisms 
including receptor-mediated endocytosis, micropinocytosis, and fusion with the plasma 
membrane, or interact with the exosome without uptake, via binding of cell surface 
receptors30. The effects that the delivery of exosomal contents have on the recipient cells 
are myriad, and can be both beneficial and deleterious. Exosomes from mesenchymal 
stem cells, for example, have been shown to have widespread antioxidant and anti-
inflammatory effects that could have therapeutic potential31. On the other hand, exosomes 
have also been shown to carry and disseminate known neurotoxic proteins such as 
prions32 and tau protein, a hallmark of Alzheimer’s disease33. Exosome contents are also 
subject to change in response to various stimuli, selectively packaging different proteins 
and RNA in response to conditions such as hypoxia, exposure to xenobiotic compounds 
such as ethanol, or signaling molecules like cytokines34,35. Investigation of the contents of 
exosomes under various conditions has enormous diagnostic potential, allowing for early 
detection of various cancers and many other progressive diseases36,37. In the case of HIV 
infection, there is evidence that the virus alters exosomal content both directly and 
indirectly, and utilizes the exosome secretion pathway to enhance its own reproduction 
and pathogenesis. In this review, the mechanisms by which HIV may hijack exosome 
production machinery will be discussed. The known downstream effects of exosomal 
transport of HIV elements will also be reviewed, and potential therapeutic options will be 
considered. 
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CHAPTER 2.    OVERLAP OF EXOSOMAL COMMUNICATION WITH HIV 
PATHOGENESIS 
 
 
Viral Agents Are Secreted from Infected Cells via Exosomes 
 
While the most obvious mechanism of HIV pathogenesis is the direct killing of 
infected T-cells by the replicating virus, it also has other methods of causing the 
associated inflammation, immune depletion, and neurodegeneration. It was discovered in 
the early 1990s that HIV-infected cells also secrete viral proteins directly into the 
extracellular space. For example, in 1990, Ensoli et al. described extracellular secretion 
of the HIV Tat protein from CD4 T-cells, which enhanced the growth of Kaposi’s 
sarcoma-like lesions in mice38. In 1994, Levy et al. reported that the HIV structural 
protein Vpr was present in both the serum and cerebrospinal fluid of AIDS patients39, and 
two years later, Fujii et al. reported a similar finding of soluble Nef protein in patient 
sera40. 
 
In general, the secretion of these proteins is proportional to viral load41, but is not 
necessarily eliminated by ART42, presenting a continuing health challenge for patients 
living with HIV. These secreted proteins enhance viral pathogenesis by multiple 
mechanisms, which will be discussed in more detail in Chapter 3. In brief, some viral 
proteins such as Tat and gp120, when secreted from infected cells, cause toxicity and 
neuronal loss, contributing to HAND43. This likely occurs through excitotoxic 
overstimulation of the N-methyl-D-aspartate receptor, which can trigger neuronal 
apoptosis44,45, as well as by other mechanisms. 
 
However, it only recently came to light that the secretion of free viral proteins 
into the extracellular space is not the only mechanism of HIV-mediated intercellular 
contact. In fact, recent research has shown that a number of different HIV proteins have 
been found packaged within exosomes. Lenassi et al., for instance demonstrated that the 
HIV protein Nef was packaged into exosomes in both infected and transformed T-cells46, 
and Pužar Dominkuš et al. reported similar observations in astrocytes47. This has been 
reported to be an evolutionarily conserved phenomenon, as it has also been found to 
occur in simian immunodeficiency virus, a closely related retrovirus that infects 
numerous primate species48. HIV Tat has also been found within exosomes secreted from 
transfected astrocytes49, and the same lab also observed the viral capsid protein p24 in 
vesicles collected from Jurkat T-cells50. Additionally, the viral envelope protein gp120 
was discovered by Arakelyan et al. in extracellular vesicles within stock viral 
preparations51. Perhaps the most extensive array of vesicular HIV proteins comes from a 
recent report by Anyanwu et al., who detected a large variety of viral proteins, including 
Nef, Tat, Vpr, and uncleaved Gag and Pol peptides, in extracellular vesicles collected 
from the urine of HIV patients52. It is worth noting, however, that the vesicles were not 
positively identified as exosomes, and that these results have not yet been reproduced. 
 
Not only viral proteins, but also RNA, can find its way into exosomes. In 2013, 
Narayanan et al. reported that exosomes from HIV patient sera and primary T-cells 
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infected with HIV ex vivo contained trans-activation response element (TAR) RNA53. 
TAR is part of a short untranslated region of the HIV genome that serves as a binding site 
for Tat, enhancing viral transcription. It also encodes viral microRNAs that protect 
infected cells against apoptosis54,55. The same laboratory later confirmed that TAR was 
also packaged into exosomes from infected monocytes and microglia56, and an 
independent study in Slovenia later confirmed the presence of TAR in exosomes from the 
plasma of aviremic HIV-positive subjects57. Interestingly, while Narayanan et al. reported 
little to no exosomal packaging of unspliced HIV RNA into exosomes, a follow-up study 
from the same laboratory revealed the presence of both TAR and full-length genomic 
RNA in exosomes from the plasma of HIV patients58. This supported the findings from 
another study by Columba Cabezas and Federico which found that the whole unspliced 
viral genome was readily packaged into exosomes in monocytes and transfected 
HEK293T cells in vitro59. 
 
The vesicular export of viral components is not unique to HIV. Epstein-Barr 
virus, hepatitis B virus, and Rift Valley fever virus, amongst others, also package viral 
proteins into exosomes and other extracellular vesicles60,61. Viral mRNA has been 
reported as well in extracellular vesicles derived from cells infected with human 
pegivirus, hepatitis C virus (HCV), and the fellow retrovirus human T-lymphotropic 
virus62. What may distinguish HIV from these other viruses, at least for the time being, is 
the amount of research that has been done on the potential mechanisms by which the 
packaging of its components into exosomes. 
 
In 2003, Gould et al. proposed a controversial hypothesis concerning HIV 
reproduction, dubbed the “Trojan Exosome Hypothesis”, in reference to the earlier 
Trojan Horse Hypothesis10,63. The hypothesis stated that, in addition to the canonical 
method of reproduction via direct budding from the plasma membrane, HIV has also 
evolved to interact with the exosome formation and packaging pathways, budding into 
the early endosome and being released as the MVB fuses with the cell membrane63. The 
hypothesis went so far as to suggest that the exosomal pathway may have been the origin 
of the virus itself; in other words, that HIV itself may be an exosome that acquired virus-
like replicative capability and became a distinct particle64. This controversial hypothesis 
initially had some strong support: viral particles collected from HIV-infected monocyte-
derived macrophages (MDM) bear a number of host proteins in common with exosomes, 
including the major histocompatibility complex class II and the exosomal marker proteins 
CD63 and CD8165,66. Furthermore, a study by Sherer et al. appeared to show that the viral 
polyproteins Gag and Env accumulate at the membrane of the late endosome and MVB 
and mediate assembly at those sites67. 
 
The Trojan Exosome Hypothesis quickly encountered resistance68,69. In 2007, two 
independent laboratories published reports that HIV particles localized and budded at 
invaginations in the plasma membrane of MDMs that could previously have been 
mistaken for intracellular endosomes, as they were rich in the same membrane-bound 
marker proteins, including CD63 and CD8170,71. Later, Grigorov et al. reported similar 
findings of HIV polyprotein localization to the plasma membrane in association with 
CD81 in infected T-cells72. These reports provided a potential explanation for the 
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presence of the exosomal markers in the membrane of viral particles, as well as an 
alternative interpretation of the data presented by Sherer et al. Later, Park and He and 
Coren et al. also presented findings that T-cells cells secrete exosomes and viral particles 
by separate processes, as exosomes package cellular beta-actin protein, whereas virions 
do not50,73. 
 
 
Mechanisms of Exosomal Packaging of HIV Elements 
 
While the Trojan Exosome Hypothesis remains a subject of discussion and 
debate, research by the original proponents of the hypothesis was foundational in 
uncovering some of the mechanistic elements behind the secretion of viral proteins, 
particularly Gag, into extracellular vesicles, if not specifically exosomes. Fang et al. 
demonstrated that higher-order oligomerization, i.e. oligomerization of multiple Gag 
peptides, at the plasma membrane contributes to vesicular export of the polypeptide by an 
apparently sequence-independent process74. There has been very little research regarding 
how higher-order oligomerization affects protein loading into the MVB or canonical 
exosomes, however, so the relevance and implications of this phenomenon with regard to 
exosomal transport of host or viral proteins are not yet understood. 
 
The Gag and Env polyproteins, as reported by Jolly et al. and others, localize to 
regions of the plasma membrane that are enriched in tetraspanins such as CD81 and 
CD63, prior to assembly and budding72,75. Jager et al. have shown that Gag can interact 
directly with CD81 and CD9, and Booth et al. demonstrated that association between Gag 
and CD81 at the plasma membrane led to secretion of Gag within extracellular 
vesicles64,76. It should be noted though, that while Booth et al. refer to these vesicles as 
“exosomes”, they are not derived from the MVB. Rather they bud directly from the 
plasma membrane, much like a virus64. These vesicles are referred to in current parlance 
as ‘ectosomes’, and while they share much in common with exosomes with regard to 
their protein profile and process of membrane budding and scission, they feature less 
specific packaging with regard to their contents77. Nevertheless, the regions of the plasma 
membrane that are enriched with these tetraspanins, referred to as tetraspanin-enriched 
microdomains (TEMs), in addition to being sites of HIV aggregation and budding78, are 
also sites for membrane invagination and early endosome formation, the first step in 
exosome biogenesis. This is evidenced by their enrichment in the intraluminal vesicles of 
the MVB relative to the endosomal and plasma membranes79. In 2013, Perez-Hernandez 
et al. demonstrated that direct interactions with TEM proteins, particularly CD81, leads to 
specific packaging of proteins into exosomes28,80. Thus, while it has not yet been 
specifically demonstrated, it is likely that the localization of Gag at TEMs, primarily for 
the purpose of assembly and budding at the plasma membrane, also results in tetraspanin-
mediated packaging of Gag into endosomes, MVBs, and ultimately exosomes. 
Significantly, given the capability to bind to other viral elements such as Env and 
genomic RNA in order to facilitate virion assembly81, this may be a mechanism by which 
those elements are sorted into exosomes as well, though this hypothesis has yet to be 
demonstrated. 
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A similar phenomenon may also occur with lipid rafts. Lipid rafts are regions of 
the membrane that are rich in cholesterol and unsaturated fats. Much like TEMs, lipid 
rafts serve as sites of viral assembly and budding82,83. There are also some reports that 
lipid rafts may be preferentially endocytosed and exported via exosomes84,85. There is 
also evidence, as reported by Hogue et al. and others from the same group, that Gag can 
induce overlap of lipid rafts and TEMs to enhance viral assembly and budding, though 
the implications for exosome formation and packaging are not clear at this time83,86. 
 
Another mechanism for viral protein packaging is via the ESCRT machinery. 
Some elements of the ESCRT complex, which plays a part in regulating the creation, 
cargo sorting, and release of vesicles, are known to interact with HIV and contribute to 
viral budding26,27. The HIV Gag peptide has two short amino acid domains that are 
known to bind elements of the ESCRT complex, both within the C-terminal p6 protein. 
The first is the primary late assembly domain, with the sequence PTAP (Pro-Thr-Ala-
Pro), which interacts with Tsg101, a subunit of ESCRT-I. The second is the auxiliary late 
assembly domain, which has the sequence LYPXnL (Leu-Tyr-Pro-Xaan-Leu) and 
interacts with Alix, an ESCRT-III-associated mediator of vesicle creation87,88. As the 
ESCRT complex is closely involved in the formation and loading of exosomes, Alix and 
Tsg101 are also often associated with them, to the degree that they are frequently used as 
secondary exosomal markers89. Given the known associations between these elements of 
the ESCRT complex and Gag, as well as their role in the sorting of proteins to exosomes, 
it is likely that they may specifically load Gag and potentially other viral proteins into 
exosomes as well, though this has not yet been demonstrated. 
 
Little has been reported concerning the mechanisms by which HIV Tat protein 
may be incorporated into exosomes, though Mele et al. speculated on this subject in their 
recent review of the mechanisms of Tat secretion90. One method they suggest is by 
association of Tat with phosphatidylinositol-4,5-bisphosphate, a phospholipid that 
facilitates direct secretion of Tat across the plasma membrane via binding and pore 
formation. Phosphatidylinositol-4,5-bisphosphate is present within the membrane of the 
early endosome and MVB, and could allow Tat to translocate from the cytosol into the 
intraluminal vesicles of the MVB, much as it has been demonstrated to do at the plasma 
membrane84,90. Mele et al. also suggest another potential mechanism: that Tat may bind 
to transcribed viral TAR RNA, or to host miRNAs, tethering itself to them as they are 
packaged into exosomes by RNA binding proteins. Sutaria et al. recently engineered an 
HIV Tat/Lamp2a fusion protein that, when paired with a pre-miRNA target containing 
the sequence for the TAR loop, dramatically enhances loading of the RNA into 
extracellular vesicles positive for Tsg10191. However, this loading process was mediated 
by the Lamp2a peptide, which is membrane-bound and packaged into the MVB under 
physiological conditions, and does not demonstrate that normal Tat-TAR binding is 
sufficient to facilitate loading either viral element into exosomes. 
 
As for loading of TAR RNA itself, as yet not much is known. In 2013, Narayanan 
et al. reported the presence of TAR in exosomes collected both in vitro and ex vivo. In 
their study, they also found Dicer and Drosha, two principle proteins of the RNA 
interference machinery, of which Dicer is known to bind and process TAR53,92. A cancer 
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study by Melo et al. found that Dicer could be loaded into exosomes via interaction with 
CD43, a membrane anchor protein93. As such, packaging of TAR could be facilitated by 
CD43-mediated transport of TAR-bound Dicer, similar to the mechanism demonstrated 
by Sutaria, et al with their Lamp2a fusion protein. Janas et al. have also proposed a 
general mechanism of exosomal RNA loading mediated by direct interaction between 
sequence motifs of RNA molecules with the lipid raft-like domains of the MVB outer 
membrane94. While the canonical TAR sequence does not contain any of the specific 
motifs reported by Janas, and there is no supporting evidence that this phenomenon 
occurs in the case of TAR packaging, it remains a potential avenue of viral RNA 
packaging worth further investigation. 
 
Perhaps the most research into the packaging of HIV elements into exosomes has 
concerned the viral protein Nef. Nef is a nonstructural accessory protein that facilitates 
viral infection and pathogenesis by interacting with a multitude of cellular pathways, 
including endocytosis and intracellular trafficking95. Its packaging into extracellular 
vesicles has been well established in T-cells and transfected HEK293 cells96,97, and it has 
been found to be secreted via both exosomes and other microvesicles, depending on the 
cell of origin46. One mechanism that could be at play is association with lipid rafts. It has 
been well established that Nef binds and anchors to lipid raft domains of the plasma 
membrane, enabling some but not all of its pathogenic effects98,99. This association, along 
with the previously mentioned enrichment of lipid rafts in MVBs85 may lead to 
piggybacking of the tethered Nef protein into exosomes100. Work by Ali et al. has shown 
that Nef has multiple sequence motifs, mostly within the first 70 amino acids from the N-
terminus, that are necessary for its exosomal secretion101. A follow-up study by the same 
group identified a five amino acid sequence, dubbed the secretion modification region, 
that facilitated exosomal packaging though binding with mortalin, a heat shock protein 
with a known ability to contribute to vesicular protein sorting102,103 Nef is also able to 
greatly enhance exosome and microvesicle secretion from T-cells and transfected HeLa 
cells by a mechanism that has not yet been fully identified46,104. 
 
 The diversity of HIV elements that can be sorted into exosomes, of the 
mechanisms involved in that process, and of the types of potential sources of those 
exosomes, creates a complex picture of the role of those vesicles in HIV pathogenesis 
(Table 2-1). Viral elements may be loaded to differing extents or by distinct processes in 
various infected cell types, possibly contributing to the multiple pathogenic consequences 
of HIV-exosomal uptake that are discussed in Chapter 3. 
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Table 2-1. HIV elements packaged within exosomes and their effects 
 
HIV Element Source Effect Reference 
Nef protein Plasma Enhanced amyloid beta 
secretion 
Khan et al., 2016105 
  Activation-induced 
T-cell death 
 
Raymond et al., 2011106 
 T-cells Activation-induced 
T-cell death 
Lenassi et al., 201046 
   Konadu et al., 2015107 
  Viral reactivation from 
latency 
Arenaccio et al., 2014108 
   Arenaccio et al., 2015109 
  n/a 
 
Muratori et al. 2009104 
 MDMs Inflammatory cytokine 
production 
 
Arenaccio et al., 2015109 
 Microglia Reduced BBB integrity 
 
Raymond et al., 2016110 
 Astrocytes n/a Pužar Dominkuš et al., 
201747 
 Transfected 
HeLa cells 
Activation-induced 
T-cell death 
 
Lenassi et al., 201046 
 Transfected 
HEK cells 
Activation-induced 
T-cell death 
Raymond et al., 2011106 
  n/a 
 
Campbell et al. 200896 
Tat protein T-cells Activation of viral 
promoter 
 
Rahimian and He, 201649 
 Astrocytes Activation of viral 
promoter 
Ibid.  
  Neurite shortening and 
neurotoxicity 
 
Ibid. 
 Transfected 
HEK cells 
Activation of viral 
promoter 
Ibid. 
  Viral reactivation from 
latency 
Tang et al, 2018111 
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Table 2-1.      (Continued) 
 
  
HIV Element Source Effect Reference 
Gag protein MDMs Enhanced infection 
 
Kadiu et al. 2012112 
 T-cells n/a 
 
Narayanan et al., 201353 
Env protein T-cells n/a 
 
Ibid. 
 n/a Enhanced infection 
 
Arakelyan et al., 201751 
TAR RNA  Plasma Enhanced infection 
 
Narayanan et al., 201353 
 T-cells Protection against 
extrinsic apoptosis 
Ibid. 
  Inflammatory cytokine 
production 
Sampey et al., 2016113 
  n/a 
 
Barclay et al., 201756 
 MDMs Inflammatory cytokine 
production 
Sampey et al., 2016113 
 Microglia n/a 
 
Barclay et al., 201756 
Viral miRNAs MDMs Inflammatory cytokine 
production 
Bernard et al., 2014114 
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CHAPTER 3.    CONSEQUENCES OF EXOSOMAL DELIVERY OF HIV 
ELEMENTS 
 
 
Packaging of viral contents into exosomes allows for their transport to other cells, 
expanding the reach of the virus’s various destructive effects on the host. One 
consequence of this exosomal delivery is the reactivation of viral replication from latent 
cells. Tang et al. artificially loaded exosomes from transfected HEK293T cells with HIV 
Tat protein, and treated the exosomes to primary HIV-infected resting CD4+ T-cells. The 
exosomal Tat reactivated HIV replication in those cells through binding at the 5’ long 
terminal repeat portion of the genome, the site of the TAR sequence111. Kadiu et al. 
demonstrated that exosomes and microvesicles from infected MDM, which were positive 
for Gag-derived peptides, enhanced the infectivity of the virus during co-treatment to 
MDM, by an unclear mechanism112. 
 
A series of papers from an Italian laboratory recently explored how exosomes 
from infected cells can induce viral replication. They found that infected T-cells released 
exosomes containing active ADAM17, a cellular protease which induced activation and 
replication of HIV in recipient T-cells. This packaging of ADAM17 only occurred if the 
exosomes contained HIV Nef, as cells infected with mutant strains that had Nef which 
was incapable of binding to membranes failed to package either protein or to activate 
downstream viral replication115. In a follow-up study, they found that the exosomal 
ADAM17 induced this activation via cleavage of pro-TNF-α to the mature form of the 
proinflammatory cytokine108. Further research demonstrated that this phenomenon also 
occurs with exosomes derived from HIV-infected MDMs as well109. 
 
A likely secondary consequence of the mechanism proposed by Arenaccio et al. is 
inflammation resulting from the activation of both infected and uninfected resting T-cells 
via TNF-α. But that is not the only means by which exosomes from HIV-infected cells 
may provoke inflammation. Sampey et al. showed that exosomes bearing TAR RNA 
induce secretion of pro-inflammatory cytokines, specifically TNF-ß and IL-6, from 
MDM via binding to the toll-like receptor 3 protein and subsequent activation of the NF-
kB pathway113. Bernard et al. also showed the proinflammatory potential of exosomal 
packaging of viral RNA. They demonstrated that primary human alveolar macrophages 
secreted exosomes containing viral microRNAs (dubbed vmiR88 and vmiR99) that 
stimulated activation of recipient macrophages which then released TNF-a. This 
induction was likely mediated by binding of the guanine and uracil-rich single-stranded 
vmiRNAs to toll-like receptor 8 and stimulation of the NF-kB pathway114. It is also of 
note that NF-kB directly enhances transcription of the HIV genome through binding to its 
5’ LTR region116, which indicates that viral mechanisms of inducing inflammation are 
likely to also promote further HIV replication117. 
 
Another avenue of HIV pathogenesis is immunodeficiency through the depletion 
of uninfected bystander T-cells. In the report by Lenassi et al. mentioned previously, 
exosomal Nef protein from infected T-cells caused activation-induced apoptosis in 
uninfected recipient cells46. Raymond et al. and Konadu et al. have both published similar 
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observations of vesicular Nef inducing apoptosis in T-cells, though notably not in 
MDMs106,107. A study by Muratori et al. showed that exosomal Nef induced expression 
and secretion of the Fas ligand, a mediator of activation-induced T-cell death104. This is 
an established mechanism of Nef-mediated immunotoxicity118, however the fact that it 
occurs via exosomal transfer of Nef even in patients on ART is of great clinical 
significance. 
 
Exosomal Nef also negatively affects endothelial cells. In a recent study, 
Raymond et al. presented data demonstrating that exosomes from Nef-transfected 
microglia could disrupt the integrity of an in vitro model of the BBB. The authors further 
showed that this disruption was due at least in part to a Nef-induced downregulation of 
zona occludin-1, also referred to as tight junction protein 1, which they hypothesized 
weakened the tight junctions between endothelial cells110. The effects of secreted Nef, 
exosomal and otherwise, on tight junction integrity has led to speculation that exosomes 
containing Nef may contribute to endothelial disruption in the gut as well, though there is 
not much evidentiary support for that hypothesis as of yet119. It is also of note that other 
HIV proteins such as Tat, Vpr, and gp120 also weaken the BBB by several mechanisms, 
such as downregulation and/or oxidative stress-induced phosphorylative dysregulation of 
tight junction proteins120. While it has not yet been explicitly demonstrated, it is likely 
that exosomal transport of these proteins contributes to BBB leakiness and viral neuro-
invasion in vivo. 
 
Perhaps the most clinically significant consequence of viral exosome production 
is its potential impact on neuroinflammation, neurodegeneration, and HAND. It has been 
well established that HIV proteins are primary mediators of neurological dysfunction. For 
example, gp120, the Env-derived surface glycoprotein, induces apoptosis in neurons 
through binding with the N-methyl-D-aspartate receptor, triggering excitotoxic cell 
death44,121. Tat can also cause excitotoxicity through a similar mechanism, and also 
induces oxidative stress in neurons via downstream induction of spermine oxidase45. 
Ferrucci, Nonnemacher, and Wigdahl, have written extensively on the multiple 
deleterious effects of extracellular Vpr protein in the central nervous system, including 
disruption in action potential conduction, mitochondrial disruption, induction of oxidative 
stress, and triggering p53-mediated apoptosis in astrocytes122. Systems of intercellular 
communication such as exosome transport, however, have only recently begun to be 
studied in the context of HIV neuropathogenesis43,123. 
 
What little research has been published on this subject so far has shown that 
vesicular transport of viral proteins within the central nervous system is likely to 
exacerbate viral neurotoxicity, much as free protein does. Rahimian and He showed that 
exosomes from Tat-transfected T-cells and astrocytes induced neurite shortening and cell 
death in recipient neurons, a phenomenon also observed when neurons are treated with 
free recombinant Tat49,124. A study by Khan et al. presented evidence that exosomes 
containing Nef protein and mRNA could induce production and secretion of amyloid beta 
protein from neuroblastoma cells in vitro105. Excessive amyloid beta production is known 
to be neurotoxic, and is a hallmark of Alzheimer’s disease as well as an indicator of poor 
prognosis in cases of age-related HAND125. Interestingly, András et al. recently 
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demonstrated that HIV exposure could induce secretion of amyloid beta in exosomes 
from BBB endothelial cells, which implies that vesicular packaging of host proteins 
could be yet another mechanism of HIV neuropathogenesis126. 
 
Taken together, recent reports strongly indicate that exosomes bearing viral 
components act as mediators for HIV pathogenesis. Delivery of viral proteins in 
particular, irrespective of viral replication, induces inflammation, weakened immunity, 
and neurodegeneration that contributes to HAND (Table 2-1 and Figure 3-1). Due to the 
failure of current ART options to counteract these effects, novel therapeutic approaches 
are a necessity for improving health and quality of life for people living with HIV. 
 
 
 
 
 
 
Figure 3-1. Mechanisms of exosome-mediated HIV pathogenesis 
In vitro and ex vivo research has uncovered multiple mechanisms by which exosomal 
transport of viral proteins and RNA can cause deleterious effects in both infected and 
uninfected recipient cells. Aβ- amyloid beta; AICD- activation-induced cell death, BBB- 
blood-brain barrier.  
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CHAPTER 4.    THERAPEUTIC OPTIONS TO COMBAT EXOSOME-
MEDIATED HIV PATHOGENESIS 
 
 
Blocking Exosomal Secretion of HIV Elements 
 
A brief review of the mechanisms of action of the mainline ART drugs used to 
combat HIV is sufficient to illustrate why those medications fail to prevent exosomal 
packaging and secretion of retroviral elements58,127. While entry, reverse transcriptase, 
and integrase inhibitors prevent the various stages prior to integration of the viral genome 
(thus averting complete infection of new cells) and protease inhibitors prevent the 
maturation of assembled virions, a gap exists between those two phases of the viral life 
cycle. The viral genomic DNA that is integrated into cells prior to ART administration 
can be transcribed, processed, translated, and secreted, despite the lack of productive 
virion formation under ART (Figure 4-1). As such, current treatment regimens are 
inadequate to combat exosome-mediated HIV pathogenesis. Novel approaches are 
necessary to interfere with the processes that occur between retroviral genome integration 
and exosomal secretion of toxic viral elements. 
 
There are several approaches that can be taken which ought to prevent exosome-
mediated viral toxicity. The first and perhaps most direct approach is to interfere directly 
with exosome secretion. By disrupting the MVB biogenesis pathway, exosome secretion 
can be nearly abolished, which necessarily would prevent exosomal transport of viral 
proteins and RNA. The experimental drug GW4869 is an inhibitor of neutral 
sphingomyelinase, a lipid-metabolizing enzyme that has been found to be essential for 
proper MVB and exosome formation. It has been found to potently inhibit exosome 
production128, and thus may be a candidate drug for disrupting a diverse array of 
exosome-mediated pathologies. Indeed, reports by Dinkins et al. and Essandoh et al. have 
shown that GW4869-induced suppression of exosome generation has beneficial effects in 
murine models of Alzheimer’s disease and sepsis, respectively129,130. However, as Gould 
et al. noted in their original proposal of the Trojan Exosome Hypothesis, inhibition of 
exosome secretion and transmission may have significantly harmful side effects. Given 
the evidence that exosomes are critical vehicles for intercellular signaling131, the 
nonspecific disruption of their generation could interfere with healthy tissue homeostasis. 
As such, global exosome suppression is not likely to be the optimal method of 
intervention. 
 
A more narrowly targeted approach would be to interfere directly with the 
exosomal packaging of viral elements. Preventing the viral agents from being sorted into 
exosomes and secreted would avert their downstream effects without hampering normal 
intercellular communication. Doing so however requires detailed knowledge of the 
mechanisms of HIV packaging, which, as discussed previously, is a field in its infancy. 
However, some discoveries have been made which may have potential applications in 
this regard. In their 2012 study in which they uncovered the binding interactions between 
the “secretion modification region” of HIV Nef protein and the human cellular protein 
mortalin, Shelton et al. synthesized a small peptide containing this same sequence102. 
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Figure 4-1. Packaging of HIV elements within exosomes despite ART 
Modern ART combats multiple stages of the retroviral life cycle, however no current 
antiretroviral drug blocks the expression of HIV proteins and RNA from integrated viral 
DNA, or their subsequent sorting into exosomes and secretion from infected cells. 
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That peptide, through competitive binding with mortalin, was able to block 
exosomal packaging of Nef without causing toxicity in transfected T-cells in vitro. Given 
even more recent research by the same laboratory showing that fusion peptides 
containing the Nef sequence may have applications in blocking exosome-mediated cancer 
metastasis132, it seems likely that it may have significant utility as an inhibitor of multiple 
exosome-mediated maladies beyond HIV. 
 
Another mechanism of viral protein sorting into exosomes that could be blocked 
is the interaction between Gag and the tetraspanin protein CD81. As discussed 
previously, both the exosomal secretion of Gag and HIV localization and assembly at the 
plasma membrane may take place at least in part through interactions with CD81 at 
TEMs. If that is the case, it follows that disruption of binding between Gag and CD81 
would blockade both processes. There is some evidence for this hypothesis: Grigorov et 
al. have shown that treatment of HIV-infected T-cells with antibodies against CD81 
reduces viral release in vitro, presumably by preventing direct interaction between Gag 
and CD81, though this mechanism has not been fully elucidated72. Interestingly, HCV 
also uses CD81 to propagate, specifically as an entry receptor133. Antibodies against 
CD81 have been used in an in vivo murine model of HCV infection, in which they were 
well-tolerated and showed potent antiviral activity as both a prophylactic and a means to 
prevent viral spread134. Much like the Nef-derived peptide inhibitor of mortalin, a number 
of peptides derived from HCV glycoproteins or from extracellular portions of CD81 have 
been developed to block HCV entry by competitive inhibition135,136. An HCV-derived 
CD81 inhibitor could also have applications for interfering with the tetraspanin’s 
interaction with HIV Gag and subsequent loading of the viral protein into exosomes, 
though this is merely speculative. 
 
 
Blocking Expression of HIV Elements 
 
Preventing the loading of HIV elements into exosomes is appealing, but it leaves 
open the possibility that viral proteins may still exert damaging effects on host tissues 
through direct secretion. To prevent such circumstances, the translation of HIV mRNA 
must be suppressed. In the past decade, a number of methods have been developed in the 
pursuit of such a goal. RNA interference, i.e. use of synthetic RNA to interfere with the 
translation, binding, or other activities of target RNAs, has shown potential as an 
antiretroviral therapeutic in vitro, and has been tested in clinical trials137. However, 
concerns over efficient delivery, and over the potential risks of viral mutation to escape 
RNA interference therapy, have hampered efforts to produce effective RNA-based 
antiretrovirals138,139. Nevertheless, RNA interference therapy may yet prove useful in the 
future, if not as a standalone ART option then as a supplemental therapy given in 
combination with more traditional ART drugs to suppress the translation and export of 
HIV proteins in exosomes. 
 
The transcription of integrated retroviral DNA is arguably an even more desirable 
stage of the HIV life cycle to target for preventing exosome-mediated toxicities. 
Preventing transcription, rather than translation, would suppress the expression of both 
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viral proteins and HIV-derived miRNA, which are also packaged and secreted into 
exosomes53,57. While there are some cellular factors that can promote transcription of the 
HIV genome, the viral Tat protein is the most appealing target for inhibition of 
transcription, as its interaction with TAR RNA is essential for significant expression of 
viral genes, and because it has no close cellular homologs140. Some of the first Tat 
inhibitors were developed in the 1990s, and were simply circularized TAR RNA decoys 
that could compete with genomic TAR to bind Tat and inhibit viral transcription141. Tat-
mimetic peptides that bind TAR have also been investigated, with some having potential 
efficacy in inhibiting reverse transcription as well81. More current research into inhibition 
of retroviral transcription has focused on small molecule Tat inhibitors, both in terms of 
discovery of novel inhibitors and repurposing of existing drugs142. For an example of the 
latter, Hayashi et al. recently reported that levosimendan, an FDA-approved drug used in 
the treatment of heart failure, effectively blocked interactions between Tat and the HIV 
genomic 5’ long terminal repeat, indicating its potential use in ART as a transcription 
inhibitor with an already-established safety record in patients143. Another group has 
developed a novel inhibitor of Tat, didehydro-Cortistatin A (dCA), which interferes with 
viral transcription and elongation at Tat’s TAR-binding site142. In a recent publication, 
the same group presented evidence that, in addition to direct inhibition of Tat-mediated 
transcription, dCA is also able to silence further viral expression through epigenetic 
modifications that restrict the HIV promoter144. The authors go so far as to propose that 
this epigenetic silencing may present a “functional cure” for HIV by permanently 
blocking viral transcription in infected patients, though of course much more research 
would be necessary to substantiate those claims. Regardless, the established direct anti-
transcriptional effects of dCA or another Tat-TAR inhibitor could be sufficient to block 
the expression and loading of both HIV proteins and RNA molecules into exosomes. 
 
Each approach to treating exosome-mediated HIV pathogenesis has pros and 
cons. Global suppression of exosome secretion is likely excessively broad in its effects, 
while specific blocking of known mechanisms of viral exosome loading may be too 
narrow. RNA interference therapy would block the expression of HIV proteins, but could 
prove ineffective due to mutation of the viral genome. That leaves blockade of 
transcription of the viral genome with perhaps the greatest potential for novel 
therapeutics. Transcription inhibitors, by blocking the expression of any viral elements, 
should in principle suppress any exosome-mediated viral toxicities, and would also serve 
as a novel class of ART drugs as well, closing the previously described gap in current 
treatment paradigms 
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CHAPTER 5.    CONCLUSION 
 
 
It has become evident that HIV is deeply integrated with the pathways of 
exosome biogenesis. It assembles at the same membrane regions through interactions 
with tetraspanins and lipid rafts. Its major pathogenic elements interact directly with the 
host protein and RNA sorting machinery by multiple apparently distinct mechanisms. 
HIV elements are not only sorted into exosomes, but can facilitate loading of host 
proteins as well, to pathogenic ends. While discussion continues regarding the origin of 
these interactions (by divergence from a common vesicular pathway or through selection 
for retroviral “hijacking” of established cellular phenomena), the consequences are 
quickly becoming apparent. Exosomal transport of HIV proteins and RNA could 
potentially contribute to chronic inflammation, leakiness of gut or BBB endothelia, and 
long-term neurological dysfunction. It may also contribute to other HIV-associated organ 
and tissue damage mediated by viral elements, such as HIV-associated nephropathy145. 
The full scope of viral pathogenesis by means of exosomal transport has yet to be fully 
explored. 
 
Current ART regimens cannot protect infected individuals from exosome-
associated viral toxicities. Modern antiretrovirals are designed to prevent either the 
formation of mature virions or the infection of new cells. This tactic is sufficient to 
suppress viral load and restore CD4 T-cell counts to healthy levels, but does not address 
the root cause of exosome-mediated pathogenesis: transcription and translation of the 
viral genome. Put simply, as long as latently infected cells are capable of producing 
functional viral RNA and proteins, exosome-associated HIV toxicities will persist under 
current ART. This fact underscores the need for novel treatment stratagems to combat 
this portion of the HIV life cycle. The ideal solution would be the discovery of the 
elusive functional cure for HIV infection, be it by “shock and kill”146 or “block and 
lock”144 approaches, by targeted gene editing to eliminate functional proviral DNA147. 
However, until such time as a safe and effective cure is found, alternative antiretroviral 
drugs are needed. HIV transcription inhibitors would eliminate the source of the problem, 
but any intervention that is able to abrogate the exosomal packaging and transmission of 
viral elements is likely to have a robust therapeutic effect and to have a long-term 
positive impact on the health and quality of life of people living with HIV. 
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